Table 1 Baseline characteristics of 248 eligible participants in the ZINC trial for HIV disease among alcohol users, 2013–2015
From: Per-protocol analysis of the ZINC trial for HIV disease among alcohol users
Baseline variable | Placebo group (N = 126) | Zinc group (N = 122) | All |
|---|---|---|---|
Gender, N (%) | |||
Male | 90 (71%) | 90 (74%) | 180 (73%) |
Female | 36 (29%) | 32 (26%) | 68 (27%) |
Depressive symptoms in the previous 7 days, N (%) | |||
Yes | 50 (40%) | 54 (45%) | 104 (42%) |
No | 75 (60%) | 66 (55%) | 141 (58%) |
Unknown | 1 (< 1%) | 2 (< 1%) | 3 (< 1%) |
Heavy drinking in the previous 7 days, N (%) | |||
Yes | 93 (74%) | 91 (75%) | 184 (74%) |
No | 33 (26%) | 31 (25%) | 64 (26%) |
Injection drug use in the previous 30 days, N (%) | |||
Yes | 47 (38%) | 44 (36%) | 91 (37%) |
No | 77 (62%) | 77 (64%) | 154 (63%) |
Previous diagnosis of cardiovascular disease, N (%) | |||
Yes | 5 (4%) | 5 (4%) | 10 (4%) |
No | 121 (96%) | 117 (96%) | 238 (96%) |
Hepatitis C virus infection | |||
Yes | 113 (90%) | 105 (86%) | 222 (89%) |
No | 13 (10%) | 17 (14%) | 26 (11%) |
Age in years, median [IQR] | 33 [30, 37] | 33 [30, 37] | 33 [30, 37] |
CD4 cell count in cells/mm3, median [IQR] | 480 [304, 683] | 443 [290, 693] | 462 [298, 691] |
HIV RNA in log10 copies/mL, median [IQR] | 4.53 [3.73, 5.02] | 4.30 [3.44, 5.12] | 4.43 [3.56, 5.05] |
VACS index, median [IQR] | 24 [18, 31] | 24 [18, 31] | 24 [17, 35] |